Veramyst - (27.5 mcg/spray ; Nasal)

Generic Name	Fluticasone Furoate	Innovator	GlaxoSmithkline
Dosage	27.5 mcg/spray ; Nasal	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Indicated for the treatment of the symptoms of seasonal and perennial allergic rhinitis in patients 2 years of age and older
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
******

Chronology Of Events